meta_pixel
Tapesearch Logo
Log in
SaaS Interviews with CEOs, Startups, Founders

632: Recursion enzyme company raises $23M, launched in 2013 now 40 people with drugs ready for market with CEO Christopher Gibson

SaaS Interviews with CEOs, Startups, Founders

Nathan Latka

Ceo, Entrepreneurs, Founders, Software, Business, Entrepreneurship, Saas, Startups

4.6683 Ratings

🗓️ 17 April 2017

⏱️ 21 minutes

🧾️ Download transcript

Summary

Christopher Gibson. He’s the co-founder and CEO of Recursion Pharmaceuticals, a biotech company leveraging the latest automation, computation and biological tools to perform drug discovery at scale. Chris holds a BS in bioengineering, a BA in managerial studies, and a bioengineering PhD from the University of Utah.

Famous Five:

  • Favorite Book? – The Hard Thing About Hard Things
  • What CEO do you follow? –  Perry Fell
  • Favorite online tool? — Slack
  • Do you get 8 hours of sleep?— 5.3 to 5.4
  • If you could let your 20-year old self, know one thing, what would it be? – Chris wished he knew where he was going to go so he could get to where he is now, faster

 

Time Stamped Show Notes:

  • 01:42 – Nathan introduces Chris to the show
  • 02:12 – Recursion shortcuts the long, arduous path of drug discovery into the market
    • 02:24 – Recursion combines the best elements of biology, automation, and computation
  • 02:34 – Recursion partners with large pharmaceutical companies
  • 02:45 – Recursion partnered with Sanofi Genzyme
    • 02:51 – Sanofi had drugs that didn’t end up in the market
  • 03:10 – The challenges involved in being target-based
  • 04:00 – Recursion earns from partnerships and royalties
    • 04:20 – Recursion also has an internal pipeline for the drugs that they’ve developed themselves
    • 04:43 – Recursion doesn’t earn from the internal pipeline
  • 05:51 – Recursion and what they receive from their partners
    • 06:28 – There are partnerships with very, little upfront
    • 06:34 – There are partnerships that have 8 figures, upfront
    • 06:46 – The number of scientists that will work on the drug is also considered
    • 07:22 – If Recursion is successful with their deals, they get royalties
    • 08:38 – The royalties’ lifeline
  • 08:56 – Recursion has 40 people 
  • 09:25 – Recursion was launched in 2013
    • 09:34 – They sat in their office until January 2014
  • 10:01 – Chris was part of a program where he was paid a stipend, so he broke even
  • 10:20 – Chris’ parents were excited about his PhD
  • 10:37 – Recursion has raised $19M in equity and $5M non-diluted from grants and private foundations
  • 11:28 – Recursion’s valuation as a platform company
    • 12:14 – If Recursion will be successful, they will impact the society in a big way
    • 12:41 – It is vision-based
  • 12:54 – First year revenue was 6 figures
  • 13:12 – “Our deals have been strategic in terms of the way we put them together”
  • 13:45 – 2017 target
  • 16:10 – The Famous Five

 

3 Key Points:

  • Different sources of revenue benefit a company.
  • The valuation of your company depends on how your company is currently performing and how well they will perform in the industry.
  • First year revenue isn’t always nil.

 

Resources Mentioned:

  • The Top Inbox  – The site Nathan uses to schedule emails to be sent later, set reminders in inbox, track opens, and follow-up with email sequences
  • Organifi – The juice was Nathan’s life saver during his trip in Southeast Asia
  • Klipfolio – Track your business performance across all departments for FREE
  • Acuity Scheduling – Nathan uses Acuity to schedule his podcast interviews and appointments
  • Host Gator – The site Nathan uses to buy his domain names and hosting for the cheapest price possible
  • Audible – Nathan uses Audible when he’s driving from Austin to San Antonio (1.5-hour drive) to listen to audio books
  • Freshbooks – Nathan doesn’t waste time so he uses Freshbooks to send out invoices and collect his money. Get your free month NOW
  • Show Notes provided by Mallard Creatives

Transcript

Click on a timestamp to play from that location

0:00.0

This is the top, where I interview entrepreneurs who are number one or number two in their industry in terms of revenue or customer base.

0:09.4

You'll learn how much revenue they're making, what their marketing funnel looks like, and how many customers they have.

0:16.1

I'm now at $20,000 per talk.

0:18.3

Five and six million.

0:19.3

He is hell bent on global domination. We just broke our $100,000 unit sold mark Five and six million. He is hell-bent on global domination.

0:21.2

We just broke our 100,000 unit sole mark.

0:23.9

And I'm your host, Nathan Latka.

0:27.7

Many of you who I've met in person have seen my unbelievable dashboards that I built.

0:32.2

You know, I'm an analytics-like crazy person.

0:35.0

I love the data.

0:36.1

And I love presenting the data and beautiful

0:37.9

dashboards that my team can use on their mobile devices, their phones, and TVs throughout

0:42.5

the office. Now the way I do this without having to hire a big development team is at

0:47.4

Nathanlaka.com forward slash analytics. It's using a company called Clipfolio and I'll tell

0:52.5

you more later on in the show how I use them.

0:54.9

It's Nathanlacka.com forward slash analytics.

0:57.7

Top tribe, you know I don't have a lot of time to waste.

1:00.3

That's why I use fresh books to send out invoices and make sure I'm collecting my money.

1:05.8

To get your free month, go to Nathan Latka.com forward slash fresh books and enter the top in the How Did You Hear

1:12.2

About Us section? Guys, coming up today, you're in for Treated. It's episode 632. You're going to learn

1:16.9

from the recursion CEO. It's an enzyme company, so health technology. They raised $23 million

1:22.1

launched in 2013. Now they have 40 people and they're about to release a new drug to the market.

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from Nathan Latka, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Nathan Latka and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2025.